Eagle Pharmaceuticals Acquires Acacia Pharma for Over $103 Million

Eagle Pharmaceuticals is gaining a potential blockbuster drug through its $103 million purchase of Acacia Pharma.

Under the agreement, the company now has access to Barhemsys (amisulpride), an antiemetic approved by the FDA for prevention and rescue treatment of postoperative nausea and vomiting. Eagle projects annual revenue for Barhemsys of $2.7 billion annually in the U.S. alone.

The company is also gaining Byfavo (remimazolam), a benzodiazepine that is FDA approved for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Byfavo is projected to earn up to $0.4 billion in the U.S. per year.

The purchase deal is expected to be completed between mid-May and June 30.